We demonstrated through our knockout studies that GPT2-driven glutaminolysis maintains the TCA cycle and OXPHOS activity, allowing the ovarian cancer cells to become resistant to platinum-based chemotherapy. This evidence concerns the gene GPT2 and ovarian carcinoma.